Marinus Pharmaceuticals, Inc. updated revenue guidance for the fiscal year 2023. For the year, the Company now expects ZTALMY net product revenues of between $18.5 and $19 million; this represents an increase from the previous guidance of between $17 and $18.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | -3.97% | -11.92% | -87.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.76% | 73.06M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023